There is strong evidence for the beneficial clinical effects that BRAF and MEK inhibitors have in metastatic melanoma, increasing tumor immunogenicity, but the onset of resistance mechanisms makes them a temporary solution in many cases. This evidence concerns the gene MAP2K7 and metastatic melanoma.